Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Microbiotix, Inc.

US Government As Represented by the Secretary of the Army

Albert Einstein College of Medicine

Terry L Bowlin

Nellikunja J Prakash

Sai P Sunkara

John D Williams

Arnab Basu

Debra M Mills

Norton P Peet

Michael L Edwards

Bing Li

Kartik Chandran

Paul S Liu

David M Stemerick

John M Dye

Donald T Moir

Zachary D Aron

Jay P Barbor

Kelly N Lively

Peter J Nash

The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GP) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

Broad spectrum inhibitors of filoviruses

The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell.

Inhibitors of viral entry into mammalian cells

This invention relates to a method of potentiating cell-mediated immunity which comprises administering to a patient a cell-mediated immunity potentiating amount of a compound of the formula:

Method of potentiating cell-mediated immunity utilizing polyamine

The present invention relates to a method of treating a patient suffering from a neoplastic disease state comprising administering to said patient an effective antineoplastic amount of N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine in conjunctive therapy with an effective antineoplastic amount of a cytotoxic agent selected from the group consisting of an antineoplastic vinca alkaloid, an antineoplastic antibiotic, an antineoplastic antimetabolite and an antineoplastic platinum coordination complex, wherein a synergistic antineoplastic effect results.

Method of treating cancer by conjunctive therapy with N,N.sup.1

Method of treating cancer by conjunctive therapy with

The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-amine substituted adenosine analogs.

5'-amine substituted adenosine analogs as immunosuppressants

The present invention relates to certain novel polyamine compounds of the formula: ##STR1## wherein Z is a saturated (C.sub.2 -C.sub.6) alkylene moiety, each R group independently is hydrogen, methyl, ethyl, or n-propyl with the provisos that both R groups cannot be hydrogen and that R is hydrogen or methyl when Z is a branched chain alkylene; or a pharmaceutically acceptable acid addition salt thereof.

Polyamine derivatives as antineoplastic agents

This invention relates to a method of effecting immunosuppression in a patient in need thereof, comprising co-administering to said patient an effective amount of an immunosuppressive agent, wherein said immunosuppressive agent is not an ornithine decarboxylase inhibitor, and an effective amount of an ornithine decarboxylase inhibitor.

Method of effecting immunosuppression

Certain Castanospermine ester derivatives are disclosed to be effective in treating retroviral infections including HIV infections and are thus useful in the treatment of AIDS and ARC.

Anti-retroviral castanospermine esters

Ornithine decarboxylase inhibitors when administered in conjunction with autologous LAK cells and interleukin-2 provide for an enhanced treatment of neoplastic disease states. This enhancement is provided by the ability of an ornithine decarboxylase inhibitor to reduce tumor load and to enhance interleukin-2 production in T helper cells.

Growing community of inventors

Maineville, OH, United States of America

Terry L Bowlin